HC Wainwright&Co.:重申Vanda Pharma(VNDA.US)评级,由买入调整至买入评级,目标价由18.00美元调整至18.00美元。万达生物制药(VNDA.US)公司简介:万达生物制药公司是一家生物制药公司,从事疗法的开发和商业化,以满足高度未满足的医疗需求并改善患者的生活。其商业产品组合包括三种产品,HETLIOZ用于治疗非24小时睡眠-觉醒障碍(非24小时)和Smith-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.